Work

Rapid and Durable Responses With the Syk/jak Inhibitor Cerdulatinib in a Phase 2 Study in Relapsed/refractory Follicular Lymphoma—alone or in Combination With Rituximab

Year: 2019

Type: article

Study design: Clinical Trial

Source: Hematological Oncology

DOI: 10.1002/hon.30_2629

Authors: S.D. Smith, J. Munoz, D.A. Stevens, S.M. Smith, T.A. Feldman, J.C. Ye, S. de Vos, B.T. Hess, C.B. Miller, J.L. Khatcheressian, M.R. Birrell, J.M. Leeds, G.P. Coffey, P.B. Conley, G.C. Michelson, J.T. Curnutte, P.A. Hamlin

Institutions: Seattle Cancer Care Alliance, University of Washington, University of Chicago, Fred Hutch Cancer Center, Banner MD Anderson Cancer Center, Norton Healthcare, Hackensack University Medical Center, University of Michigan, U-M Rogel Cancer Center, University of California, Los Angeles, Medical University of South Carolina, MUSC Hollings Cancer Center, Saint Agnes Hospital, Virginia Cancer Institute, Portola Pharmaceuticals (United States), Memorial Sloan Kettering Cancer Center

Language: English

Topic: Lymphoma Diagnosis and Treatment

Subfield: Pathology and Forensic Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2951906678

FWCI: 0.36

Cites:

Cited by: 2

Related to: 10